As of May 22
| +2.32 / +1.08%|
The 7 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 125.00, with a high estimate of 230.00 and a low estimate of 99.00. The median estimate represents a -42.69% decrease from the last price of 218.11.
The current consensus among 8 polled investment analysts is to Hold stock in Synageva BioPharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.